Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Research Article

In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.

R N Jones, M E Erwin
R N Jones
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M E Erwin
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.36.1.233
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Ro 09-1227 is a novel 7-position catechol-substituted parenteral cephalosporin that also has a 3-position radical similar to previously described cephems. The Ro 09-1227 spectrum was slightly wider than that of ceftazidime against members of the family Enterobacteriaceae tested, principally because of greater activity against species producing Richmond-Sykes type I beta-lactamases. Ro 09-1227 was also more active than ceftazidime against some strains producing extended-spectrum plasmid-encoded beta-lactamases, such as TEM-3, -4, -5, -6, -7, and -9, SHV-2 and -3, and CAZ-2. Most strains of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Acinetobacter spp. were also more susceptible to Ro 09-1227 than cefotaxime, ceftriaxone, cefoperazone, and ceftazidime. Haemophilus influenzae (MIC for 90% of strains tested [MIC90], 0.5 micrograms/ml), Neisseria gonorrhoeae (MIC90, 0.015 micrograms/ml), and Moraxella (Branhamella) catarrhalis (MIC90, 0.5 micrograms/ml) were also Ro 09-1227 susceptible. Ro 09-1227 activity against important gram-positive cocci was most comparable to that of ceftazidime. Bacteroides fragilis (MIC90, greater than 32 micrograms/ml) and the enterococci (MIC90, greater than 32 micrograms/ml) were resistant to Ro 09-1227. These in vitro results indicate that this catechol-substituted cephalosporin may be useful as an empiric agent, especially for some isolates resistant to currently available broad-spectrum cephalosporins.

PreviousNext
Back to top
Download PDF
Citation Tools
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
R N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy Jan 1992, 36 (1) 233-238; DOI: 10.1128/AAC.36.1.233

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
R N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy Jan 1992, 36 (1) 233-238; DOI: 10.1128/AAC.36.1.233
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596